雷帕鸣是哪里产的？

Where is Leipaming produced? Sirolimus was originally manufactured by Wyeth Pharmaceuticals Company and later by Pfizer in the United States.

Sirolimus (temsirolimus) is the only marketed drug that specifically inhibits mTOR kinase. mTOR is a multifunctional kinase that belongs to the phosphatidylinositol 3-kinase (PI3K) protein kinase family. It is an effector protein downstream of the PI3K/PKB (proteinkinaseB, chemicalbook white kinase B, AKT) signaling pathway. Its substrate mainly controls the synthesis of proteins closely related to cell growth and proliferation. Excessive activation of the PI3K-AKT-mTOR signaling pathway in cancer cells is common in clear cell renal cell carcinoma.

Although rapamin (sirolimus) is structurally homologous to TRL (Tacmlimus, FK506) and binds to the same immune binding protein, their mechanisms of action are different. Rapamin (sirolimus) and FK506 are structural homologs. Although they act on the same receptor, their immune action mechanisms are different. FK506 inhibits the proliferation of T lymphocytes from the G0 phase to the G1 phase, while sirolimus blocks signaling through different cytokine receptors and blocks the progression of T lymphocytes and other cells from the GI phase to the S phase. Compared with FK506, sirolimus can block the calcium-dependent and calcium-independent signaling pathways P1 of T lymphocytes and B lymphocytes.

Currently, rapamin (sirolimus tablets) on the market abroad is cost-effective. For detailed drug information, please consult your medical companion or travel service.